R. Lamy

2.6k total citations
32 papers, 633 citations indexed

About

R. Lamy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, R. Lamy has authored 32 papers receiving a total of 633 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in R. Lamy's work include Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (14 papers) and Cancer Immunotherapy and Biomarkers (13 papers). R. Lamy is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Lung Cancer Research Studies (14 papers) and Cancer Immunotherapy and Biomarkers (13 papers). R. Lamy collaborates with scholars based in France, United States and Luxembourg. R. Lamy's co-authors include C. Chouaïd, Florian Guisier, H. Doubre, P. Fournel, M. Pérol, Charles Ricordel, Henri Janicot, F. Viñas, Olivier Bylicki and Jérôme Dauba and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Antimicrobial Chemotherapy.

In The Last Decade

R. Lamy

30 papers receiving 627 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Lamy France	11	500	425	142	124	65	32	633
Yi-Sheng Huang China	11	471 0.9×	589 1.4×	162 1.1×	140 1.1×	47 0.7×	27	728
Millie Das United States	17	405 0.8×	388 0.9×	145 1.0×	287 2.3×	68 1.0×	63	719
Melina E. Marmarelis United States	14	359 0.7×	312 0.7×	98 0.7×	114 0.9×	54 0.8×	61	590
Franco Vito Piantedosi Italy	12	519 1.0×	432 1.0×	124 0.9×	92 0.7×	76 1.2×	14	698
Giovanni Palazzolo Italy	15	528 1.1×	474 1.1×	85 0.6×	211 1.7×	63 1.0×	47	786
Tsukihisa Yoshida Japan	14	377 0.8×	456 1.1×	67 0.5×	122 1.0×	72 1.1×	34	650
Andrzej Każarnowicz Poland	5	422 0.8×	304 0.7×	83 0.6×	149 1.2×	109 1.7×	14	578
Charles Ricordel France	14	467 0.9×	529 1.2×	81 0.6×	198 1.6×	40 0.6×	74	787
Ruqin Chen United States	11	511 1.0×	559 1.3×	88 0.6×	161 1.3×	42 0.6×	22	764
Emiddio Barletta Italy	12	395 0.8×	336 0.8×	82 0.6×	92 0.7×	81 1.2×	28	584

Countries citing papers authored by R. Lamy

Since Specialization

Citations

This map shows the geographic impact of R. Lamy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Lamy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Lamy more than expected).

Fields of papers citing papers by R. Lamy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Lamy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Lamy. The network helps show where R. Lamy may publish in the future.

Co-authorship network of co-authors of R. Lamy

This figure shows the co-authorship network connecting the top 25 collaborators of R. Lamy. A scholar is included among the top collaborators of R. Lamy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Lamy. R. Lamy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Treut, J. Le, G. Le Garff, Olivier Bylicki, et al.. (2022). Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy. Lung Cancer. 174. 45–49. 8 indexed citations

Mordant, Pierre, Solenn Brosseau, B. Milleron, et al.. (2022). Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study. Clinical Lung Cancer. 24(1). 1–10. 4 indexed citations

Auliac, J.B., I. Monnet, Laurent Greillier, et al.. (2021). Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study). Lung Cancer. 161. 122–127. 3 indexed citations

Paleiron, N., Radj Gervais, Laurence Gamé, et al.. (2021). Management of patients with synchronous head-and-neck and lung cancers. Journal of Cancer Research and Therapeutics. 18(Suppl 2). S160–S164. 5 indexed citations

Girard, Nicolas, M. Duruisseaux, Virginie Avrillon, et al.. (2020). 1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Annals of Oncology. 31. S865–S865. 1 indexed citations

Auliac, J.B., Florian Guisier, R. Lamy, et al.. (2020). Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study). OncoTargets and Therapy. Volume 13. 13299–13305. 2 indexed citations

Guisier, Florian, Catherine Dubos‐Arvis, F. Viñas, et al.. (2020). Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018. Journal of Thoracic Oncology. 15(4). 628–636. 215 indexed citations

Geier, Margaux, R. Lamy, G. Robinet, et al.. (2020). Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung. JTO Clinical and Research Reports. 2(4). 100129–100129. 12 indexed citations

Bylicki, Olivier, Florian Guisier, I. Monnet, et al.. (2020). Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma. Medicine. 99(3). e18726–e18726. 22 indexed citations

10.

Geier, Margaux, R. Descourt, R. Corre, et al.. (2020). Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer. Cancer Medicine. 9(19). 6923–6932. 4 indexed citations

11.

Baize, Nathalie, I. Monnet, Laurent Greillier, et al.. (2019). OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial. Journal of Thoracic Oncology. 14(10). S246–S246. 5 indexed citations

12.

Auliac, J.B., M. André, J. Madelaine, et al.. (2019). Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer. Targeted Oncology. 14(3). 307–314. 7 indexed citations

13.

Amrane, Karim, Margaux Geier, R. Corre, et al.. (2019). First line pembrolizumab for NSCLC with PD-L1 TPS > 50% in a first French real life cohort. Annals of Oncology. 30. v617–v617.

14.

Geier, Margaux, R. Descourt, R. Corre, et al.. (2018). Real life second-line nivolumab in advanced non-small cell lung cancer: A French observational multicenter study of 259 patients (ABCT-IMMUNOBZH). 2(5). 5 indexed citations

15.

Geier, Margaux, R. Descourt, R. Corre, et al.. (2018). MA08.10 Real-Life Intracerebral Efficacy of Nivolumab in Non-Small Cell Lung Cancer Patients with Brain Metastases. Journal of Thoracic Oncology. 13(10). S384–S385. 10 indexed citations

16.

Corre, R., R. Gervais, Florian Guisier, et al.. (2017). Octogenarians with EGFR-mutated non-small cell lung Cancer (NSCLC) treated by Tyrosine Kinase Inhibitor (TKI): A multicentric real world study assessing tolerance and efficacy. OCTOMUT study GFPC 07-15. Annals of Oncology. 28. v485–v485. 1 indexed citations

17.

Greillier, Laurent, Julien Mazières, I. Monnet, et al.. (2015). Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study). BMC Cancer. 15(1). 857–857. 14 indexed citations

18.

Auliac, J.B., Charles Fournier, Clarisse Audigier-Valette, et al.. (2015). Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study. Targeted Oncology. 11(2). 167–174. 15 indexed citations

19.

Gonçalvès, Anthony, Marine Gilabert, E. François, et al.. (2012). BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Annals of Oncology. 23(11). 2799–2805. 176 indexed citations

20.

Lemerle, S., et al.. (1988). Teicoplanin in combination therapy for febrile episodes in neutropenic and non-neutropenic paediatric patients. Journal of Antimicrobial Chemotherapy. 21(suppl A). 113–116. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact